Back

Impact of baseline C-reactive protein on the efficacy and safety of rivaroxaban monotherapy in atrial fibrillation and stable coronary artery disease: a post-hoc AFIRE analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention: biomarkers to optimise outcomes Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Sachie Kasukabe

Tohoku University, Sendai (Japan)

5 More presentations in this session

Presentation thumbnail
Association of clinical, lifestyle, and genetic risk factors with outcomes after coronary artery bypass grafting
Mr J. Lambermont (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Interleukin-6 inclusion adds value to the SMART risk score for prediction of cardiovascular death in patients with established ASCVD
Professor F. Kahles (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Optimizing long-term cardiovascular risk stratification: incorporating biomarkers into the atherosclerotic cardiovascular disease very high-risk definition
Doctor J. Cheng (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease
Professor D. Capodanno (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Recover with INOCA: A randomized, prospective study of a cardiac rehabilitation program in patients with ischemia with nonobstructive coronary artery disease (INOCA)
Miss M. Calvo Lopez (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention: biomarkers to optimise outcomes
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Inflammation and long-term outcomes after first-time direct current cardioversion for atrial fibrillation: a nationwide register study
thumbnail
Congress Presentation
Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study
thumbnail
Congress Presentation
Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources